Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting.
-- April 28, 2009, 2:20 p.m. CDT - "A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC)." AUA Late-Breaking Science Forum to be held from 1:00 p.m. to 2:30 p.m. CDT. Room W375 at McCormick Place -- April 28, 2009, 10:30 a.m. to 12:30 p.m. CDT - Abstract #1408: "Preclinical Evaluation of the TRPM8 Ion Channel Agonist D-3263 for Benign Prostatic Hyperplasia." Poster presentation to occur in the Benign Prostatic Hyperplasia: Basic Research session. Room W375B at McCormick Place -- April 28, 2009, 4:30 p.m. CDT - IMPACT data webcast conference call
The IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study evaluated PROVENGE(R) (sipuleucel-T), Dendreon's investigational product candidate for men with advanced prostate cancer representing the first in a new class of active cellular immunotherapies specifically designed to engage the patient's own immune system against cancer. Dendreon announced last week that the IMPACT trial met its primary endpoint of improving overall survival compared to a placebo control.
To access the live conference call, dial 1-877-675-4753 (domestic) or 719-325-4864 (international). The call also will be audio webcast and will be available from the Company's website at http://www.dendreon.com/ under the "Investor/Webcasts and Presentations" section. There will be a slide presentation to accompany the call, which will also be available on this section of the Dendreon website. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-203-1112 (domestic) or 719-457-0820 (international); the conference ID number is 6483399. The replay will be available from 8:00 p.m. ET, April 28, 2009 until midnight April 29, 2009. In addition, the webcast will be archived for on-demand listening for 30 days at http://www.dendreon.com/.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.
CONTACT: Jennifer Cook Williams, Investor Relations of Dendreon Corporation, +1-206-829-1500; or media, Katherine Stueland of WeissComm Partners, +1-312-608-0320, firstname.lastname@example.org, for Dendreon Corporation
Web Site: http://www.dendreon.com/
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 24, 2009|
|Previous Article:||Neovasc Inc. Reports Year 2008 Financial Results.|
|Next Article:||Champion Enterprises Reports First Quarter 2009 Results.|